Naoko Takebe

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.670Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Papers

Driven by 50 papers — median percentile 40. Top paper: “Atezolizumab for Advanced Alveolar Soft Part Sarcoma”.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

Journal of Clinical Oncology(2022)10.1200/jco.22.00830

N/A

2.2DataRank · unranked

97 citations

Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal +15 more

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11519

N/A

1.8DataRank · unranked

50 citations

Geraldine O’Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin Fino +15 more

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02838

N/A

0.722DataRank · unranked

122 citations

Katherine A. Janeway, David R. Patton, Cynthia L. Winter, Brent Coffey, P. Mickey Williams +16 more

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

Cancer Cell(2020)10.1016/j.ccell.2020.10.015

N/A

0.698DataRank · unranked

104 citations

Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton +41 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0.546DataRank · unranked

37 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0.457DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2145

N/A

0.416DataRank · unranked

15 citations

Naoko Takebe, Shivaani Kummar, Albiruni R. Abdul Razak, Sant P. Chawla, Suzanne George +13 more

Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

Oncotarget(2021)10.18632/oncotarget.27887

N/A

0.360DataRank · unranked

10 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Jerry M. Collins, Joel M. Reid, Richard Piekarz +18 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0.358DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2568

N/A

0.292DataRank · unranked

6 citations

Brian M. Alexander, Nathalie Y.R. Agar, Manmeet S. Ahluwalia, Arati Desai, Jörg Dietrich +14 more

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

JCO Precision Oncology(2024)10.1200/po.24.00327

N/A

0.260DataRank · unranked

4 citations

Opeyemi A. Jegede, David M. Jackman, James A. Zwiebel, Robert J. Gray, Victoria Wang +17 more

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0100

Top 60%

0.248DataRank

Top 60%4 citations

Fathi Elloumi, Sudhir Varma, Prashant Khandagale, Ukhyun Jo, Suresh Kumar +18 more

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3104

N/A

0.208DataRank · unranked

3 citations

W. Kimryn Rathmell, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A. Trikalinos +9 more

Demographic Trends in NCI-sponsored Early-phase Clinical Trials (2000–2023): A Cohort Study

Cancer Discovery(2025)10.1158/2159-8290.cd-25-0112

Top 70%

0.165DataRank

Top 70%2 citations

Elad Sharon, Naoko Takebe, Maria Farooq

Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway

iScience(2021)10.1016/j.isci.2021.103173

N/A

0DataRank · unranked

18 citations

Ukhyun Jo, Junko Murai, Shinsaku Fukuda, Naoko Takebe, Yves Pommier +1 more

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

The Lancet(2022)10.1016/s0140-6736(22)01390-3

N/A

0DataRank · unranked

68 citations

Ruitao Lin, Christopher R. Flowers, Shanda Finnigan, Lisa M. Cordes, Yoko Fukuda +7 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449

Journal of Neuro-Oncology(2022)10.1007/s11060-022-04193-3

N/A

0DataRank · unranked

13 citations

Charles Nock, Xiaobu Ye, Robert Buerki, Susan M. Chang, Glenn J. Lesser +12 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

SLFN11’s surveillance role in protein homeostasis

Oncoscience(2022)10.18632/oncoscience.560

N/A

0DataRank · unranked

1 citations

Ukhyun Jo, Yasuhiro Arakawa, Naoko Takebe, Yves Pommier, Yasuhisa Murai

1417 Utilization of immune-based response criteria in NCI-CTEP sponsored immunotherapy clinical trials

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.1417

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, O’Hara Geraldine, Naoko Takebe +2 more

Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors

The Journal of Clinical Pharmacology(2022)10.1002/jcph.2053

N/A

0DataRank · unranked

0 citations

Andrew T. Ralya, Thomas R. Larson, Renee M. McGovern, Sarah A. Buhrow, Joseph M. Covey +6 more

Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11

Cancers(2021)10.3390/cancers13184601

N/A

0DataRank · unranked

51 citations

Yasuhisa Murai, Naoko Takebe, Anish Thomas, Yves Pommier, Ukhyun Jo

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad085

N/A

0DataRank · unranked

95 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

Cancer Research(2021)10.1158/0008-5472.can-20-2694

N/A

0DataRank · unranked

55 citations

Ukhyun Jo, Junko Murai, Lisa M. Jenkins, Shar-yin N. Huang, Sirisha Chakka +6 more

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5564

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Mohamad A. Salkeni, Naoko Takebe, Ning Ma +12 more

Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13610

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, Geraldine O’Sullivan Coyne, Naoko Takebe +2 more

Data from SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

(2023)10.1158/0008-5472.c.6513573.v1

N/A

0DataRank · unranked

0 citations

Ukhyun Jo, Junko Murai, Lisa M. Jenkins, Shar-yin N. Huang, Sirisha Chakka +6 more

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0402

N/A

0DataRank · unranked

24 citations

Yasuhiro Arakawa, Astrid Zimmermann, Daiki Taniyama, Makito Mizunuma, Lisa M. Jenkins +6 more

Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0085

N/A

0DataRank · unranked

13 citations

Ukhyun Jo, Suresh Kumar, Nai-Yun Sun, Fathi Elloumi, Anish Thomas +18 more

Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0093

N/A

0DataRank · unranked

13 citations

Christophe E. Redon, Liton Kumar Saha, Andy D. Tran, Anjali Dhall, Robin Sebastian +6 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-x

N/A

0DataRank · unranked

1 citations

Naoko Takebe, Alice P. Chen, Shivaani Kummar, Richard Piekarz, Brian F. Kiesel +5 more

Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids

SLAS DISCOVERY(2025)10.1016/j.slasd.2025.100222

N/A

0DataRank · unranked

9 citations

Zahra Davoudi, Nathan P. Coussens, Thomas Silvers, Joel Morris, Naoko Takebe +5 more

Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0435

N/A

0DataRank · unranked

7 citations

Elisabetta Marangoni, Fathi Elloumi, Rémi Montagne, Sudhir Varma, Yanghsin Wang +11 more

Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids

SLAS DISCOVERY(2025)10.1016/j.slasd.2025.100230

N/A

0DataRank · unranked

5 citations

Thomas S. Dexheimer, Thomas Silvers, Phillip R. Sanchez, Li Chen, Melinda G. Hollingshead +4 more

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0582

N/A

0DataRank · unranked

1 citations

Thomas S. Dexheimer, Nathan P. Coussens, Thomas Silvers, Raymond G. Fox, Samantha B. Kemp +7 more

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0305

N/A

0DataRank · unranked

1 citations

Nataliya V. Uboha, Naoko Takebe, Kit Tam, Philippe L. Bédard, Kari B. Wisinski +13 more

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2617

N/A

0DataRank · unranked

0 citations

Geraldine O’Sullivan Coyne, Ashley Bruns, Larry Rubinstein, Naoko Takebe, Sarah J. Shin +10 more

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3155

N/A

0DataRank · unranked

0 citations

Jennifer Zlott, Jared C. Foster, Sarah J. Shin, Geraldine O’Sullivan Coyne, Naoko Takebe +5 more

Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models

Academia oncology.(2025)10.20935/acadonco7726

N/A

0DataRank · unranked

0 citations

Naoko Takebe, Thomas S. Dexheimer, Thomas Silvers, Nathan P. Coussens, Melinda G. Hollingshead +2 more

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10007

N/A

0DataRank · unranked

3 citations

Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, P. Mickey Williams +16 more

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa061

N/A

0DataRank · unranked

33 citations

Lou Staudt, Naoko Takebe, David A. Wheeler, Linghua Wang, Maria Cardenas +34 more

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10008

N/A

0DataRank · unranked

2 citations

Olive S. Eckstein, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Naoko Takebe

Indexed papers

Top data-sharing exemplar

Papers